STOCK TITAN
  1. Home
  2. Sec-filings
  3. NSPR
  4. [Form 4] InspireMD, Inc. Insider Trading Activity

InspireMD (NSPR) director granted 132,076 restricted shares vesting 2027

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

InspireMD, Inc. director Paul Stuka reported a grant of 132,076 shares of common stock as restricted stock on January 14, 2026. The award was reported at a price of $0 per share and will vest on January 14, 2027, provided he continues to serve, bringing his directly held common shares to 523,704.

The filing also notes 444,195 shares of InspireMD common stock held indirectly through Osiris Investment Partners, L.P. Mr. Stuka is the managing member of the general partner of Osiris and may be deemed to beneficially own these securities, but he disclaims beneficial ownership except to the extent of his pecuniary interest. No transaction occurred with respect to these Osiris-held shares; they are reported for informational purposes.

Positive

  • None.

Negative

  • None.
Insider Stuka Paul
Role Director
Type Security Shares Price Value
Grant/Award Common Stock 132,076 $0.00 --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 523,704 shares (Direct); Common Stock — 444,195 shares (Indirect, See Footnote)
Footnotes (1)
  1. These shares of common stock represent shares of restricted stock that shall vest on January 14, 2027 (the "One Year Grant Anniversary Date"), subject to the Reporting Person's continued service. These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Stuka Paul
(Last) (First) (Middle)
C/O INSPIREMD, INC.
6303 WATERFORD DISTRICT DRIVE, SUITE 215
(Street)
MIAMI FL 33126
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
InspireMD, Inc. [ NSPR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
01/14/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/14/2026 A 132,076(1) A $0 523,704 D
Common Stock 444,195 I See Footnote(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These shares of common stock represent shares of restricted stock that shall vest on January 14, 2027 (the "One Year Grant Anniversary Date"), subject to the Reporting Person's continued service.
2. These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
Remarks:
Exhibit 24.1: Power of Attorney
/s/ Michael Lawless, Attorney-in-Fact for Paul Stuka 01/16/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did InspireMD (NSPR) report for Paul Stuka?

On January 14, 2026, InspireMD director Paul Stuka reported a grant of 132,076 shares of common stock as restricted stock at a reported price of $0 per share.

When do Paul Stuka’s new InspireMD restricted shares vest?

The 132,076 restricted shares granted to Paul Stuka will vest on January 14, 2027, subject to his continued service with the company.

How many InspireMD shares does Paul Stuka hold directly after this Form 4?

Following the reported grant, Paul Stuka beneficially owns 523,704 shares of InspireMD common stock in direct ownership.

Did any transaction occur in the Osiris-held InspireMD shares?

No. The filing states that no transaction was effected with respect to the Osiris-held securities; they are included in the Form 4 for informational purposes only.

Does Paul Stuka claim full beneficial ownership of the Osiris-held InspireMD shares?

No. The filing explains that Paul Stuka disclaims beneficial ownership of the Osiris-held shares except to the extent of his pecuniary interest in them.